Introduction
Ebola and Marburg viruses are two rare but severe viral diseases caused by viruses in the Filoviridae family. Both can cause outbreaks of severe illness, including fever, weakness, muscle pain, gastrointestinal symptoms and, in severe cases, bleeding. They also share important epidemiological characteristics, including transmission through direct contact with infected blood or other body fluids.
However, Ebola and Marburg are not the same disease: they are caused by different viruses and have important differences in their history, natural hosts, available vaccines and specific treatments.
Ebola vs Marburg: Key Differences
| Feature | Ebola | Marburg |
| Disease name | Ebola disease | Marburg virus disease |
| Virus | Orthoebolavirus | Orthomarburgvirus |
| Virus family | Filoviridae | Filoviridae |
| First recognized | 1976 | 1967 |
| Natural host | Fruit bats | Egyptian fruit bat (Rousettus aegyptiacus) |
| Initial animal-to-human transmission | Likely contact with infected wildlife | Exposure to infected fruit bats, particularly in caves/mines |
| Himan-to-human transmission | Direct contact with infected blood/body fluids and contaminated materials | Direct contact with infected blood/body fluids and contaminated materials |
| Incubation period | 2-21 days | 2-21 days |
| Main symptoms | Fever, fatigue, muscle pain, headache, sore throat, vomiting, diarrhoea, abdominal pain, rash | Fever, severe headache, malaise, muscle pain, diarrhoea, abdominal pain, vomiting, rash |
| Haemorrhagic manifestations | May occur, usually later | May occur, usually later |
| Case-fatality rate | Average ~50%; historical outbreaks 25–90% | Average ~50%; historical outbreaks 24–88% |
| Diagnosis | RT-PCR, antigen detection, antibody tests, virus isolation | RT-PCR, antigen detection, antibody tests, virus isolation |
| Specific treatment | Approved monoclonal antibody treatments exist for Ebola virus disease | No approved specific antiviral treatment |
| Vaccine | Licensed vaccines are available for Ebola virus disease | No approved vaccine currently |
| Major prevention | Isolation, PPE, contact tracing, safe burials, vaccination where applicable | Isolation, PPE, contact tracing, safe burials and infection preventio |
| Airborne spread | No | No |
Comparative Analysis of Ebola and Marburg Viruses
Although Ebola and Marburg diseases are caused by different viruses, they have many clinical similarities. Both can begin with sudden fever, headache, muscle pain and weakness and may progress to vomiting, diarrhoea, abdominal pain and, in severe cases, haemorrhagic manifestations. The incubation period for both diseases can range from 2 to 21 days. Because their symptoms can resemble other infectious diseases, including malaria and other viral haemorrhagic fevers, laboratory confirmation is essential.
A major difference between Ebola and Marburg virus diseases is the availability of vaccines and specific treatments. For Ebola virus disease caused by Ebola virus, a licensed vaccine, Ervebo, is available and WHO recommends its use in outbreak settings. Two monoclonal-antibody treatments—ansuvimab (mAb114) and REGN-EB3 (Inmazeb)—are recommended for Ebola virus disease. In contrast, there are currently no approved vaccines or antiviral treatments for Marburg virus disease, although candidate vaccines and therapeutics are being investigated.
The diseases also differ in their known animal associations. Fruit bats are considered important natural hosts for filoviruses, while the Egyptian fruit bat (Rousettus aegyptiacus) is specifically recognized as the natural host of Marburg virus. Human infections can occur following exposure to infected animals and can subsequently spread between people through direct contact with infected blood, secretions or other body fluids, as well as contaminated materials.
Despite advances in prevention and treatment, both diseases remain important public-health concerns because they can cause outbreaks with high mortality. WHO estimates an average case-fatality rate of around 50% for both Ebola disease and Marburg virus disease, although rates have varied substantially between outbreaks. Early supportive care—including rehydration and management of symptoms—can improve survival. Effective outbreak control also depends on rapid diagnosis, isolation and clinical care, infection prevention and control, contact tracing, surveillance, safe and dignified burials, and community engagement.
References
World Health Organization. Ebola disease. Geneva: WHO; 2025. WHO Ebola disease fact sheet
World Health Organization. Marburg virus disease. Geneva: WHO; 2025. WHO Marburg virus disease fact sheet
World Health Organization. Ebola vaccines. Geneva: WHO; 2026. WHO Ebola vaccines Q&A
World Health Organization. Marburg virus disease: Questions and answers. Geneva: WHO; 2025. WHO Marburg Q&A